An Open-label Extension to Study 200952 to Evaluate the Long-term Safety, Tolerability and Pharmacodynamics of Albiglutide Liquid Drug Product in Subjects With Type 2 Diabetes Mellitus

Registration

Registration

NCT02750930

Study type

INTERVENTIONAL

Phase

PHASE4

Masking

NONE

Status

TERMINATED

Enrollment

8

Start

2016-10-07

Primary completion

2017-03-21

Lead sponsor

GlaxoSmithKline

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG:Albiglutide; DEVICE:Auto-injector

Results posted

TRUE

Registered primary outcomes

• Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) [Up to Week 34]
• Number of Participants With Physical Examination Abnormalities [Up to Week 34]
• Number of Participants With Hematology Values of Potential Clinical Importance (PCI) [Up to Week 34]
• Number of Participants With Clinical Chemistry Parameters of PCI [Up to Week 34]
• Number of Participants With Clinically Significant Urinalysis Abnormalities by Dipstick Method [Up to 26 weeks]
• Number of Participants With Pulse Rate Values of PCI [Up to Week 34]
• Number of Participants With Systolic and Diastolic Blood Pressure of PCI [Up to Week 34]
• Number of Participants With Clinically Significant Findings for 12-lead ECG [Up to Week 34]
• Number of Participant With Positive Results of Anti-albiglutide Antibody Production Over Time [Up to Week 34]